Moderate

Eosinophilic oesophagitis — long-term management

EoE · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Chronic Th2-mediated oesophageal inflammation causing dysphagia and food impaction, defined by ≥15 eosinophils/hpf with symptoms after excluding other causes. Management targets histological remission to prevent fibrostenotic remodelling.

Red flags

  • Acute food bolus impaction
  • Progressive solid-food dysphagia with weight loss
  • Chest pain/odynophagia suggesting perforation after impaction or dilatation
  • Failure to achieve remission despite adherence

Assessment

Differential diagnosis

  • Gastro-oesophageal reflux disease
  • PPI-responsive oesophageal eosinophilia
  • Achalasia/motility disorder
  • Oesophageal stricture (peptic/caustic)
  • Hypereosinophilic syndrome
  • Crohn's oesophageal involvement

Investigations

  • Endoscopy: rings, furrows, exudates, crepe-paper mucosa, strictures
  • ≥6 biopsies from proximal and distal oesophagus (≥15 eos/hpf)
  • Exclude GORD and other causes clinically
  • Allergy assessment if food-trigger elimination planned
  • Barium swallow if stricture suspected before dilatation

Management

  • Confirm diagnosis: typical symptoms + ≥15 eos/hpf on biopsy with secondary causes excluded
  • Choose first-line therapy: PPI, topical corticosteroid, dietary elimination, or biologic
  • Start high-dose PPI (e.g. omeprazole 20–40 mg twice daily) — effective in a substantial subset
  • Or swallowed topical steroid: budesonide orodispersible 1 mg twice daily, or fluticasone swallowed
  • Advise not to eat/drink for 30 min after swallowed steroid; rinse mouth to avoid candidiasis
  • Consider empirical elimination diet (six-food or step-up 2-4-6) with dietitian support
  • Reassess symptoms AND repeat endoscopy with biopsy at 8–12 weeks to confirm histological remission
  • Dilate symptomatic fibrostenotic strictures cautiously after inflammation controlled
  • For refractory disease consider dupilumab (anti-IL-4Rα) at specialist centre
  • Continue maintenance therapy — relapse is near-universal on stopping
  • Monitor periodically for symptom relapse and growth/nutrition in young adults

Drugs & doses

Budesonide orodispersible 1 mg PO twice daily (then 0.5 mg twice daily maintenance)
Omeprazole 40 mg PO twice daily
Fluticasone propionate 220–440 mcg swallowed twice daily
Dupilumab 300 mg SC weekly (refractory, specialist)

Disposition

Outpatient GI clinic with dietitian; specialist/tertiary referral for refractory disease, biologics or complex strictures.

Complications & pitfalls

  • Food bolus obstruction
  • Fibrostenotic stricture formation
  • Oesophageal perforation (impaction or dilatation)
  • Oral candidiasis from topical steroid
  • Nutritional compromise from food avoidance

Exam pearls

  • Histological remission (<15 eos/hpf) is the treatment goal, not symptom relief alone — re-scope to confirm
  • PPI responders still have EoE, not GORD — the old PPI-REE distinction is abandoned
  • Dilate only after medical control of inflammation to reduce perforation risk
  • Orodispersible budesonide is purpose-formulated and outperforms off-label asthma steroids

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.